---
document_datetime: 2023-09-21 18:22:47
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/rapilysin-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: rapilysin-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.372038
conversion_datetime: 2025-12-21 11:19:24.967178
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

## For procedures finalised after 1 September 2003 please refer to module 8B.

- The Marketing Authorisation Holder submitted on 6 May 1997 an application for a Type II variation (change in shelf-life of the active ingredient), pursuant to Article 6 of Commission Regulation (EC) No 542/95 of 10 March 1995, as amended. The procedure started on 16 May 1997  and  a  positive  opinion  (EMEA/H/C/105/II/01)  was  adopted  by  the  CPMP  on  23  July 1997. This variation did not require any amendment  to the Community  Marketing Authorisation.
- The Marketing Authorisation Holder submitted on 26 May 1997 an application for a Type I variation, following a Type  II evaluation procedure (additional filtration step in the manufacturing of the finished product), pursuant to Article 4 of Commission Regulation (EC) No.  542/95  of  10  March  1995,  as  amended.  The  procedure  started  on  30  May  1997. Supplementary information was supplied by the MAH on 12 September 1997 and a positive opinion  (EMEA/H/C/105/I/02)  was  adopted  by  the  CPMP  on  24  September  1997.  This variation did not require any amendment to the Community Marketing Authorisation.
- The Marketing Authorisation Holder submitted on 26 May 1998 an application for a Type I variation No. 15 of Annex I to the regulation (antibiotic-free preculture in the manufacturing of the active ingredient), pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995, as amended. The procedure started on 30 May 1997, and a positive opinion (EMEA/H/C/105/I/03)  was  adopted  by  the  CPMP  on  23  July  1997.  This  variation  did  not require any amendment to the Community Marketing Authorisation.
- The Marketing Authorisation Holder submitted on 26 May 1997 an application for a Type II variation (new formulation), pursuant to Article 6 of Commission Regulation (EC) No. 542/95 of  10  March  1995,  as  amended.  The  procedure  started  on  30  May  1997.  Supplementary information  was  supplied  by  the  MAH  on  8  and  31  October  1997,  and  a  positive  opinion (EMEA/H/C/105/II/04)  was  adopted  by  the  CPMP  on  19  November  1997.  The  European Commission granted a Commission Decision on 18 March 1998.
- The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  10  October  1997  an application for a Type II variation (minor change of the manufacturing process of the active ingredient),  pursuant  to  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10  March 1995, as amended. The procedure started on 24 October 1997. Supplementary information was supplied by the MAH on 9 January 1998 and a positive opinion (EMEA/H/C/105/II/05) was adopted by the CPMP on 25 February 1998. This variation did not require any amendment to the Community Marketing Authorisation.
- The  Marketing  Authorisation  Holder  submitted  on  5  December  1997  an  application  for  a Notification of a Type I variation (extension of shelf life), pursuant to Article 4 of Commission Regulation  (EC)  No.  542/95  of  10  March  1995,  as  amended.  The  procedure  started  on  10 December 1997 and supplementary information was provided by the MAH on 9 January 1998. The  Head  of  the  Human  Medicines  Evaluation  Unit  signed  a  positive  notification  on  10 February 1998 (EMEA/H/C/105/I/06) and the European Commission granted a Commission Decision on 15 April 1998.
- The Marketing Authorisation Holder submitted on 4 February 1998 an application for a type II variation  (change  in  summary  of  product  characteristics  and  package  leaflet  following  the conclusions of the PSUR), pursuant to Article 6 of Commission Regulation (EC) No. 542/95 of March 1995, as amended. The procedure started on 26 February 1998 and supplementary information was supplied by the MAH on 8 June 1998. A positive opinion (EMEA/H/C/105/II/07)  was  adopted  by  the  CPMP  on  24  June  1998  and  the  European Commission granted a Commission Decision on 5 October 1998.
- Boehringer Mannheim GmbH submitted to the EMEA on 10 July 1998 an application for a Type  II  variation  (changes  in  the  specification  of  active  substance;  deletion  of  the  two parameters  'amino  acid  analysis'  and  'residual  DNA  content'),  pursuant  to  Article  6  of

<div style=\"page-break-after: always\"></div>

Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as  amended.  The  procedure started on 24 July 1998. A positive opinion (EMEA/H/C/105/II/08) was adopted by the CPMP on  16  September  1998.  This  variation  did  not  require  any  amendment  to  the  Community Marketing Authorisation.

- The MAH submitted to the EMEA on 14 January 1999 an application for the Transfer of the Marketing Authorisation from Boehringer Mannheim GmbH, Germany to Roche Registration Limited, United Kingdom, pursuant to Article 3 of Commission Regulation (EC) No. 2141/96 of 7 November 1996, as amended. The procedure started 15 January 1999.  A positive opinion (EMEA/H/C/105/I/09) was signed by the Executive Director at the EMEA on 3 February 1999 and forwarded to the European Commission, which granted a Commission Decision 08 April 1999.
- The  Marketing  Authorisation  Holder  submitted  on  14  January  1999  an  application  for  a Notification  of  a  Type  I  variation  (change  following  modification  of  the  manufacturing authorisation), pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995,  as  amended.  The  procedure  started  on  15  January  1999.  A  positive  notification (EMEA/H/C/105/I/10) was signed by the Head of the Human Medicines Evaluation Unit on 3 February 1999 and the European Commission granted a Commission Decision on Decision 08 April 1999.
- The Marketing Authorisation Holder submitted on 17 January 2000 an application for a type II Variation (update of the Summary of Product Characteristics and Package Leaflet following the  introduction  of  an  Urgent  Safety  Restriction),  pursuant  to  Article  1(2)  of  Commission Regulation (EC) No. 542/95 of March 1995, as amended. The procedure started on 21 January 2000. A positive opinion (EMEA/H/C/105/II/11) was adopted by the CPMP on 16 February 2000 and the European Commission granted a Commission Decision on 29 May 2000.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                                                                                                                                                                               | Application number   | Type of modification   | Notification/ Opinion issued on   | Commission Decision Issued/amen ded on   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------|-----------------------------------|------------------------------------------|
| Update of summary of product characteristics and package leaflet                                                                                                                                                                                                                                                                                    | II/12                | II                     | 16.11.00                          | 22.02.01 (20.03.01)                      |
| Change in or addition of manufacturer(s) of active substance                                                                                                                                                                                                                                                                                        | I/II/13              | I/II                   | 01.03.01                          | 13.03.01                                 |
| Quality changes                                                                                                                                                                                                                                                                                                                                     | II/14                | II                     | 26.04.01                          | 11.05.01                                 |
| change in test procedure for determining the content of the two- chain reteplase protein in the bulk drug solution.                                                                                                                                                                                                                                 | I/II/15              | I/II                   | 26.04.01                          |                                          |
| Renewal of Marketing Authorisation, resulting in changes to the SPC (sections 4.6, 4.8 and 5.3) PL and labelling.                                                                                                                                                                                                                                   | R/16                 | R                      | 26.07.01                          | 9.11.01                                  |
| an update of Part II of the dossier, including an extension of the shelf-life of the finished product to 3 years.                                                                                                                                                                                                                                   | II/17                | II                     | 13.12.01                          | 27.03.02                                 |
| a correction of the IPC limit for Specific Amidolytic Activity of the Diafiltrate (IPC Sample 10) of Reteplase.                                                                                                                                                                                                                                     | I/18                 | I                      | 18.03.03                          | N/A                                      |
| change in the Production and In-Process Controls (IPC) of the Raw Material Recombinant Serin-1 Erythrina Trypsin Inhibitor (recSerETI).                                                                                                                                                                                                             | I/19                 | I                      | 25.04.03                          | N/A                                      |
| replacement of test kit by manually prepared solutions of ammonium vanadate and ammonium molybdate for routine testing of phosphate.                                                                                                                                                                                                                | I/20                 | I                      | 18.03.03                          | N/A                                      |
| deletion of a contraindication in diabetic patients (section 4.3 of the SPC) following the publication of a CPMP position statement concerning the use of iv fibrinolytics in diabetic patients. Section 2 of the PL has been updated accordingly. The MAHtook this opportunity to update the contact details of a number of local representatives. | II/21                | II                     | 22.05.03                          | 07.08.03                                 |
| an extension of the shelf-life (from 42 to 60 months) for the intermediates (recSerETI inclusion bodies).                                                                                                                                                                                                                                           | I/22                 | I                      | 24.06.03                          | N/A                                      |